@article{Trayner_K-2024_172604,
title = {Impact of the COVID-19 pandemic on HIV test uptake among people who inject drugs in the context of an HIV outbreak},
author = {Trayner, K. and Yeung, A. and Palmateer, N. and McAuley, A. and Wilkinson, M. and Craik, J. and Metcalfe, R. and Peters, E. and Shepherd, S. and Gunson, R. and Carter, D. and Sills, L. and Hutchinson, S.},
month = {apr},
year = {2024},
abstract = {Glasgow, Scotland’s largest city, has been experiencing an HIV outbreak among people who inject drugs (PWID) since 2015. A key focus of the public health response has been to increase HIV testing among those at risk of infection. Our aim was to assess the impact of COVID-19 on HIV testing among PWID in Glasgow. HIV test uptake in the last 12 months was quantified among: (1) PWID recruited in six Needle Exchange Surveillance Initiative (NESI) surveys (n = 6110); linked laboratory data for (2) people prescribed opioid agonist therapy (OAT) (n = 14,527) and (3) people hospitalised for an injecting-related hospital admission (IRHA) (n = 12,621) across four time periods: pre-outbreak (2010–2014); early-outbreak (2015–2016); ongoing-outbreak (2017–2019); and COVID-19 (2020–June 21). From the pre to ongoing period, HIV testing increased: the highest among people recruited in NESI (from 28% to 56%) and on OAT (from 17% to 54%) while the lowest was among people with an IRHA (from 15% to 42%). From the ongoing to the COVID-19 period, HIV testing decreased markedly among people prescribed OAT, from 54% to 37% (aOR 0.50, 95% CI 0.48–0.53), but increased marginally among people with an IRHA from 42% to 47% (aOR 1.19, 95% CI 1.08–1.31). In conclusion, progress in increasing testing in response to the HIV outbreak has been eroded by COVID-19. Adoption of a linked data approach could be warranted in other settings to inform efforts to eliminate HIV transmission.},
journal = {AIDS and Behavior},
publisher = {Springer Nature},
url = {https://doi.org/10.1007/s10461-024-04311-4},
}
